Wockhardt Bio AG – a subsidiary of Wockhardt Ltd and Jemincare have partnered for Wockhardt’s novel patented antibiotic WCK 4873 (INN: Nafithromycin) in the People’s Republic of China, Hong Kong, Macau and Taiwan for the treatment of community-acquired bacterial pneumonia and other respiratory tract infections.

Under the terms of the definitive agreement, Jemincare will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets. A joint steering committee has been formed to oversee the development and regulatory action. Wockhardt will receive an upfront payment and will be eligible for regulatory-linked milestone payments. Further, Wockhardt would supply the product to Jemincare and will receive royalties on net sales. Wockhardt would transfer the manufacturing technology to Jemincare at a mutually agreed time.

Dr. Habil Khorakiwala, Founder Chairman of Wockhardt Group said, “Wockhardt has been at the forefront in the fight against Anti-Microbial Resistance (AMR) which has been identified as one of the top threats by WHO. Our novel drug discovery program of around 20 years has yielded a rich pipeline of products that are at different stages of commercialization. This arrangement upholds our commitment in the fight against AMR.”

Wockhardt will continue to develop Nafithromycin for other markets including India where Phase III clinical study is ongoing. “We are happy to partner with a company of repute like Jemincare in China, which is also one of the biggest markets. We are confident that Jemincare with its excellent standing in China will do full justice to the potential of the product.”, noted Dr. Murtaza Khorakiwala, Managing Director, Wockhardt.

Dr. Mahesh Patel, Chief Scientific Officer of Wockhardt added, “Bacterial pneumonia and other respiratory tract infections trigger the highest volume of antibiotic prescriptions the world over. The prevalence of antimicrobial resistance poses a therapeutic challenge to physicians with extremely limited safer and effective therapeutic options, particularly for the most vulnerable group such as pediatric and older age group patients. Nafithromycin has been designed to overcome resistance in several respiratory pathogens. It would provide a compliance-friendly once-a-day, three-day therapy option, most appropriate for community origin respiratory infections.”

About WCK 4873 (Nafithromycin)

Nafithromycin is a novel broad-spectrum antibiotic belonging to the lactone/ketolide class for respiratory tract infections. Nafithromycin is active against an entire range of bacterial pathogens associated with community-acquired bacterial pneumonia including macrolide resistance strains which is around 80% in China and several other Asian countries. Wockhardt has completed global clinical Phase I and II studies with Nafithromycin.